NCT03173066View on ClinicalTrials.gov

Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Pulmonary Embolism
Interventions
DRUG

Ferumoxytol

ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT03173066 - Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography | Biotech Hunter | Biotech Hunter